Subtopic Deep Dive

PROTAC Protein Degraders
Research Guide

What is PROTAC Protein Degraders?

PROTACs are heterobifunctional small molecules that recruit E3 ubiquitin ligases to target proteins, inducing their ubiquitination and proteasomal degradation.

PROTACs consist of a target-binding ligand, a linker, and an E3 ligase recruiter, enabling degradation of otherwise undruggable proteins. Over 10,000 papers reference PROTAC technology since its inception. Key advances include cereblon-based degraders and structural insights into cooperative binding (Békés et al., 2022; Gadd et al., 2017).

Curated Papers

Key Challenges

Why It Matters

PROTACs target 'undruggable' proteins like transcription factors in cancer, as shown in BET degrader applications for castration-resistant prostate cancer (Raina et al., 2016, 797 citations). They expand drug discovery by enabling catalytic degradation, reducing off-target effects compared to inhibitors (Bondeson et al., 2015, 1239 citations). Therapeutic candidates have entered clinical trials, with impacts on oncology and neurodegeneration (Schapira et al., 2019).

Key Research Challenges

Linker Optimization

Linker length and composition critically affect PROTAC efficacy and selectivity, as varying lengths alter E3 ligase recruitment (Cyrus et al., 2010, 221 citations). Poor design leads to suboptimal ternary complex formation. Balancing flexibility and rigidity remains key for potency.

E3 Ligase Selectivity

Most PROTACs rely on promiscuous E3 ligases like cereblon, causing unintended degradation (Bondeson et al., 2017, 861 citations). Developing tissue-specific recruiters is needed. Structural studies reveal cooperative recognition challenges (Gadd et al., 2017).

Pharmacokinetic Hurdles

Large molecular size of heterobifunctional PROTACs impairs oral bioavailability and cell permeability. Clinical translation requires size reduction without losing activity (Békés et al., 2022). Extracellular targeting via lysosome chimaeras addresses some issues (Banik et al., 2020).

Essential Papers

PROTAC targeted protein degraders: the past is prologue

Miklós Békés, David R. Langley, Craig M. Crews · 2022 · Nature Reviews Drug Discovery · 2.7K citations

Induced protein degradation: an emerging drug discovery paradigm

Ashton C. Lai, Craig M. Crews · 2016 · Nature Reviews Drug Discovery · 1.3K citations

Catalytic in vivo protein knockdown by small-molecule PROTACs

Daniel P. Bondeson, Alina Mares, Ian E. Smith et al. · 2015 · Nature Chemical Biology · 1.2K citations

Structural basis of PROTAC cooperative recognition for selective protein degradation

Morgan S. Gadd, Andrea Testa, Xavier Lucas et al. · 2017 · Nature Chemical Biology · 1.1K citations

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Jing Lü, Yimin Qian, Martha Altieri et al. · 2015 · Chemistry & Biology · 1.1K citations

Lysosome-targeting chimaeras for degradation of extracellular proteins

Steven M. Banik, Kayvon Pedram, Simon Wisnovsky et al. · 2020 · Nature · 978 citations

Targeting transcription factors in cancer — from undruggable to reality

John H. Bushweller · 2019 · Nature reviews. Cancer · 893 citations

Reading Guide

Foundational Papers

Start with Schneekloth et al. (2004) for selective in vivo degradation concept and Sakamoto et al. (2003) for cancer protein targeting, establishing PROTAC principles.

Recent Advances

Study Békés et al. (2022) for clinical progress overview and Gadd et al. (2017) for structural mechanisms of selectivity.

Core Methods

Core techniques: heterobifunctional design with cereblon/VHL recruiters (Lü et al., 2015; Bondeson et al., 2015), linker length tuning (Cyrus et al., 2010), and lysosome chimaeras (Banik et al., 2020).

How PapersFlow Helps You Research PROTAC Protein Degraders

Discover & Search

Research Agent uses citationGraph on Békés et al. (2022, 2669 citations) to map PROTAC evolution from foundational works like Schneekloth et al. (2004), revealing high-impact E3 ligase papers. exaSearch queries 'PROTAC linker optimization cereblon' for 500+ recent hits, while findSimilarPapers expands from Lai & Crews (2016) to undruggable target degraders.

Analyze & Verify

Analysis Agent employs readPaperContent on Gadd et al. (2017) to extract ternary complex PDB structures, then runPythonAnalysis with PyMOL scripts to quantify binding cooperativity metrics. verifyResponse (CoVe) cross-checks degradation efficiency claims against Bondeson et al. (2015) data, with GRADE scoring evidence strength for E3 selectivity.

Synthesize & Write

Synthesis Agent detects gaps in E3 ligase diversity from Schapira et al. (2019), flagging needs for novel recruiters. Writing Agent uses latexEditText to draft PROTAC design sections, latexSyncCitations for 20+ refs like Raina et al. (2016), and latexCompile for camera-ready reviews; exportMermaid visualizes degradation pathways.

Use Cases

"Analyze degradation kinetics from Bondeson 2015 PROTAC data"

Research Agent → searchPapers 'Bondeson PROTAC 2015' → Analysis Agent → readPaperContent → runPythonAnalysis (pandas curve fitting on IC50 data) → matplotlib half-life plots output.

"Write a review on PROTAC clinical candidates with figures"

Synthesis Agent → gap detection on Crews papers → Writing Agent → latexGenerateFigure (ternary complex diagram) → latexSyncCitations (Békés 2022 et al.) → latexCompile → PDF review export.

"Find open-source PROTAC linker design code"

Research Agent → searchPapers 'PROTAC linker optimization' → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for QED scoring.

Automated Workflows

Deep Research workflow scans 50+ PROTAC papers via citationGraph from Crews 2004, generating structured reports on linker trends with GRADE-verified stats. DeepScan applies 7-step CoVe to validate claims in Banik et al. (2020) LYTACs, checkpointing E3 selectivity. Theorizer hypothesizes novel bifunctional degraders from Gadd et al. (2017) structures.

Try Doxa for PROTAC Protein Degraders Research

Frequently Asked Questions

What defines a PROTAC?

PROTACs are heterobifunctional molecules with a target ligand, linker, and E3 recruiter that induce ubiquitination and proteasomal degradation (Lai & Crews, 2016).

What are key PROTAC methods?

Methods include cereblon hijacking for BRD4 degradation (Lü et al., 2015) and VHL-based selective degraders with optimized linkers (Bondeson et al., 2017).

What are seminal PROTAC papers?

Foundational: Schneekloth et al. (2004, 451 citations) for chemical knockdown; Sakamoto et al. (2003, 393 citations) for cancer targets. Recent: Békés et al. (2022, 2669 citations) reviews field.

What are open problems in PROTACs?

Challenges include oral bioavailability due to size, E3 ligase restriction to few types, and extracellular protein targeting (Békés et al., 2022; Banik et al., 2020).